Kornimate/medical-research-clean huggingface dataset:
hypermetabolism in the elderly lung cancer patient

Conditions: Non-small Cell Lung Carcinoma

Summary: aging and cancer are two conditions associated with extensive metabolic changes that can cause malnutrition. however, the clinical features and the underlying mechanisms leading to malnutrition are different in these two cases. we therefore wonder how age can influence the metabolic response to cancer.

during aging, among other physiological modifications, inactivity and insulin resistance cause a progressive muscle loss associated with a decrease in resting energy expenditure (ree). in cancer, loud inflammation background also provokes a decrease in muscle mass as well as in fat mass. however, previous studies reported an increased ree, termed hypermetabolism, probably linked to inflammation. data concerning response to aggression in the elderly patient is scarce and even inexistent when it comes to cancer. the investigators hypothesize that the mitochondrial dysfunction that comes with aging and that decreases the atp rendering per unit of energy-producing nutrient oxidized increases the amount of nutrient to be consumed in order to sustain to energy needs. therefore, in this situation, elderly patients could have a higher rate or degree of hypermetabolism than younger patients. the primary objective of this study is to assess the effect of aging on the metabolic response to cancer assessed by resting energy expenditure measured by indirect calorimetry corrected by whole body fat free mass calculated from single slice ct imaging at the third lumbar vertebra. the secondary objective of this study is to point out some inflammatory or endocrine determinants of these energy metabolism changes in the cancer patient. non-small cell lung carcinoma seems to be a relevant choice for this study because it is frequently associated with cachexia and the literature reports a high rate of hypermetabolism in this cancer.

Eligibility criteria:
inclusion criteria: * non-small cell lung carcinoma exclusion criteria: * imbalanced diabetes * imbalanced dysthyroidia * surgery within two month prior inclusion * any chronic auto-immune or inflammatory disease

Keywords: aging hypermetabolism
bm characterization pilot

Conditions: Diaper Rash

Summary: this is a prospective, pilot study to explore the relationship between an infant's nutrition, skin and stool composition at different ages.


Eligibility criteria:
inclusion criteria: * infants aged 0-12 months exclusion criteria: * formula fed * use of topical or oral antibiotics or antifungals within the past 4 weeks
platelet rich therapy for scar revision

Conditions: Abdominoplasty Scar Revision

Summary: this study will evaluate the efficacy of platelet injections for use of scar therapy post abdominoplasty operations.

platelet therapy is quickly becoming an integral aspect of both medical and cosmetic procedures. most notably, platelet rich plasma (prp) has been used in surgical settings to stimulate healing and promote tissue regeneration. in the field of cosmetic medicine, prp has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. harvested prp has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis. platelet rich fibrin (prf) is the next generation of prp and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. due to a lack of anticoagulant in the tube, prf becomes a gel after 15-20 minutes of being isolated. these properties make prf useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way prp is currently used.the purpose of this study is to evaluate the efficacy of platelet rich plasma vs. platelet rich fibrin for scar therapy in abdominoplasty who are at least one-year post operation.

Eligibility criteria:
inclusion criteria: * ten (10) subjects * male and female abdominoplasty procedures at least one year ago. * must be able to provide healthy blood sample * must be available for the duration of the study and all follow ups (12 months). exclusion criteria: * pregnant and breast-feeding patients are not eligible for this study due to unstudied effects of injectables on the growing fetus and/or breast milk. * patients who have undergone other scar therapies for the same scar. * chronic health problems that may prevent the investigators from obtaining a viable blood sample, * topical infection, * any subjects who intend to have other scar procedures during the timeline of the study (12 months including punch biopsy procedures 3 months post treatment and 6 months post treatment).

Keywords: abdomen abdominoplasty scar therapy scar
life quality and mental state in patients with breast cancer

Conditions: Breast Cancer

Summary: randomized pragmatic trial to evaluate the comparative effectiveness regarding disease specific quality of life of an individualized additional complementary medicine treatment in addition to usual care with usual care only in 280 women with breast cancer


Eligibility criteria:
inclusion criteria: * diagnosed breast cancer * current usual care treatment * willing to refrain from complementary treatment for 6 months in case of randomization into the usual care group * informed consent exclusion criteria: * complementary treatment at the hospital meran in the last 6 months * no german or italian language ability * participation in other study
evaluating dysphagia in neonates with chd

Conditions: Dysphagia of Newborn

Summary: the overall goal of this study is to describe the oral motor skills of neonates born with congenital heart defects, both before and after cardiac surgery, and to evaluate current measures of feeding motor skills and feeding readiness in this population using the neonatal oral motor assessment scale (nomas) and the infant driven feeding scale. the specific aims are to: 1. describe the oral motor skills of infants with chd before surgery as compared with normal full-term newborn (\>37 weeks) using the nomas 2. describe the oral motor skills of infants with chd after surgery as compared with those same infants before surgery using the nomas. 3. determine if the current infant driven feeding readiness scale appropriately identifies which children with chd are ready for oral feeding. (a. feeding readiness scale, b. quality of nippling scale at the 1st post- operative feeding evaluation) 4. describe the unique characteristics of oral motor skills in infants with chd (ie. wide jaw excursions, poor latch, etc.) our hypothesis is that infants with chd will have dysfunctional sucking patterns before surgical repair as compared to normal newborns. this dysfunctional sucking pattern in infants with chd will have worsened post-surgery as compared to pre-surgery. in addition, the infant driven feeding scale will be utilized to predict that many infants with chd will not be ready for oral feedings, however most of those patients will go on to successfully take oral feedings.


Eligibility criteria:
inclusion criteria: * full-term newborns with normal physical exam that are delivered \> 37 weeks gestation (healthy newborn arm). or * newborn with chd born \> 37 weeks gestation, are hemodynamically stable and who require surgical correction in the first 30 days of life (chd arm). exclusion criteria: * full-term newborn arm * newborn admitted into the nicu * genetic syndromes * congenital abnormalities or signs of developmental delay · infants with chd arm * newborn requiring intubation prior to evaluation (note: infants with chd with genetic or other malformations not specifically mentioned will not be excluded due to their prevalence in this population) * down syndrome * trisomy 13, trisomy 18 * congenital anomalies of facial structure or musculature specifically cleft lip, hard or soft palate
the effectiveness and safety of neoadjuvant intravesical mitomycin-c instillation

Conditions: Bladder Cancer

Summary: the aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical mitomycin-c instillation in non-muscle invasive bladder cancer patients

study design: intervention model: single group assignment masking: open label primary outcome measures: recurrence-free survival in neoadjuvant intravesical mitomycin-c 40mg/20ml instillation group and control group. secondary outcome measures: progression-free survival in neoadjuvant intravesical mitomycin-c 40mg/20ml instillation group and control group. time to recurrence in neoadjuvant intravesical mitomycin-c 40mg/20ml instillation group and control group. change of tumor size after neoadjuvant intravesical mitomycin-c 40mg/20ml instillation. safety of neoadjuvant intravesical mitomycin-c 40mg/20ml instillation.

Eligibility criteria:
inclusion criteria: * the subjects who will undergo transurethral resection of the tumor after diagnosis of bladder cancer * male or female aged 18 or over 18 years and not more than 85 years who were diagnosed as bladder cancer * normal bone marrow function: hemoglobin \>10 g/dl, anc \>1,500/mm3, platelet count\>100,000/mm3 * normal renal function: serum creatinine ≤ 1.4 mg/dl * normal liver function: * bilirubin ≤ 1.5 times of upper normal limit * ast/alt ≤ 1.8 times of upper normal limit * alkaline phosphatase ≤ 1.8 times of upper normal limit * subjects who voluntarily decided to participate and signed the written informed consent exclusion criteria: * non-urothelial carcinoma * muscle invasive bladder cancer * subjects who underwent intravesical mitomycin-c instillation after diagnosis of bladder cancer within 3 years * prior hypersensitivity reaction history to mitomycin-c * neurogenic bladder * subjects who underwent chemotherapy due to any cancer within 6 months
a multicenter phase 3, open-label study of bosutinib versus imatinib in adult patients with newly diagnosed chronic phase chronic myelogenous leukemia

Conditions: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Summary: phase 3, 2-arm, randomized, open label trial. patients will be randomized to receive bosutinib or imatinib for the duration of the study.

the study will be open for enrollment until the planned number of approximately 500 philadelphia chromosome positive (ph+) patients have been randomized (approximately 250 ph+ patients in each treatment arm; a total of approximately 530 ph+ and ph- patients). all patients will be treated and/or followed for approximately 5 years (240 weeks) after randomization until the study has closed. patients who discontinue study therapy early due to disease progression or intolerance to study medication will continue to be followed yearly for survival for up to approximately 5 years (240 weeks) after randomization.

Eligibility criteria:
inclusion criteria: 1. molecular diagnosis of cp cml of ≤ 6 months (from initial diagnosis). 2. adequate hepatic, renal and pancreatic function. 3. age ≥ 18 years. exclusion criteria: 1. any prior medical treatment for cml, including tyrosine kinase inhibitors (tkis), with the exception of hydroxyurea and/or anagrelide treatment, which are permitted for up to 6 months prior to study entry (signature of icf) if suitably approved for use in the subject's region. 2. any past or current central nervous system (cns) involvement, including leptomeningeal leukemia. 3. extramedullary disease only. 4. major surgery or radiotherapy within 14 days of randomization. 5. history of clinically significant or uncontrolled cardiac disease. 6. known seropositivity to human immunodeficiency virus (hiv), current acute or chronic hepatitis b (hepatitis b surface-antigen positive), hepatitis c, cirrhosis or evidence of decompensated liver disease. patients with resolved hepatitis b can be included. 7. recent or ongoing clinically significant gi disorder, e.g. crohn's disease, ulcerative colitis, or prior total or partial gastrectomy. 8. history of another malignancy within 5 years with the exception of basal cell carcinoma or cervical carcinoma in situ or stage 1 or 2 cancer that is considered adequately treated and currently in complete remission for at least l2 months. 9. current, or recent (within 30 days, or 5 half-lives of investigational product) participation in other clinical trials of investigational agents and/or containing interventional procedures deemed contrary to the objectives and conduct of this trial.

Keywords: leukemia myelogenous chronic bcr-abl positive bosutinib leukemia, myeloid leukemia, myelogenous, chronic, bcr-abl positive philadelphia chromosome neoplasms by histologic type bone marrow diseases hematologic diseases translocation, genetic pathologic processes imatinib therapeutic uses pharmacologic actions molecular mechanisms of pharmacological action
effect of a 12-month pharmaceutical care program on control of severe asthma

Conditions: Asthma; Quality of Life

Summary: only a few well-designed studies have investigated the effect of pharmaceutical care on asthma patients and to date there are no published studies investigating this effect specifically on severe and refractory asthma. the objective of this study is evaluate the effect of pharmaceutical care on asthma control and quality of life (qol) of patients with severe or refractory asthma compared with pharmacist dispensation only.


Eligibility criteria:
inclusion criteria: * patients with severe/refractory asthma presenting other respiratory disease, * ≥ 18 years of age, * using high dose of inhaled corticosteroids (≥ 800mcg of budesonide or equivalent) * fev1\<60%, * regular visitor of the pharmacy and the physicians. exclusion criteria: * participation in other intervention study during this study, * living in other cities, * could not participate in all visits of the study
cast vs. splints for minimally displaced distal radius fractures in the elderly

Conditions: Radius; Fracture, Lower or Distal End

Summary: the purpose of this prospective randomized study is to add to the body of knowledge on the treatment of minimally displaced distal radius fractures in patients over 60 years of age. the investigators believe that treating minimally displaced distal radius fractures in people over 60 with a removable splint and early range of motion will provide greater patient satisfaction, fewer complications, and earlier functional returns to pre-injury for these patients compared to those treated with a short arm cast which immobilizes the limb for at least four weeks, and has been shown to lead to longer recovery and possible residual stiffness. the investigators hope to provide sufficient evidence in directing treatment that will give the most efficacious and the most satisfactory return of prior function to patients. since distal radius fractures in the elderly are common because of poorer bone quality, the elderly proportion of the population is increasing, and controlling health costs is of current concern, answering the question of which treatment produces the best results for all these concerns is of increasing importance now.


Eligibility criteria:
inclusion criteria: 1. colles' fracture - distal radius fracture with dorsal angulation, apex volar (satisfies non-operative radiographic criteria before or after reduction 2. isolated upper limb injury 3. no previous wrist fracture 4. available for follow-up 5. between 60 and 100 years of age exclusion criteria: 1. less than 60 years of age 2. fractures that do not meet non-operative criteria or are deemed unstable by surgeon, subsequently requiring surgery after first clinic visit.

Keywords: wrist fracture radius fracture elderly splint cast
an investigation to evaluate the function of a new silicon cover film and an on-top suction device to be used in a npwt system in the treatment of acute and chronic wounds

Conditions: Acute and Chronic Wounds

Summary: the aim of the investigation is to evaluate the function of two new device parts to be used in a npwt system; an on-top suction device intended to transport exudate from the wound and a silicon cover film intended to fixate the wound filler and seal tight to the skin in order to keep a moist environment.


Eligibility criteria:
inclusion criteria: 1. chronic wounds (venous, pressure or diabetic type), and acute wounds suitable for npwt therapy according to the investigator's judgment 2. 1cm2 ≤ wound size ≤ 200cm2 3. male or female, 18 years and above 4. signed informed consent form 5. subject understands the written patient information exclusion criteria: 1. need for frequent dressing changes, i.e.\<48 hours between the changes 2. critical ischemia (for wound healing) according to investigator's judgement 3. malignancy in the wound and/or wound margin 4. target ulcer previous not successfully treated with npwt within 48 hours 5. poorly controlled diabetes according to investigators judgement. 6. osteomyelitis which has been left untreated 7. infection which has been left untreated 8. high risk for bleeding complications 9. exposed blood vessels, organs or nerves 10. current or within 3 months treatment with chemotherapy or irradiation 11. known hypersensitivity to the dressing material 12. expected technically impossible to seal the film to achieve a vacuum treatment 13. expected non compliance with the clinical investigation plan (cip) 14. pregnancy 15. subjects not suitable for the investigation according to the investigator's judgement 16. subjects previously included in this investigation 17. subjects included in other ongoing clinical investigation at present or during the past 30 days
effectiveness of us-guided pcnl different positions in renal stones treatment

Conditions: Percutaneous Nephrolithotomy; Renal Stones; Ultrasound Therapy; Complications

Summary: the aim of this study is to compare the effectiveness of ultrasound-guided percutaneous nephrolithotomyin different positions supine, prone positions and flank suspend supine position in renal stones treatment.

percutaneous nephrolithotomy (pcnl) has become the choice of modality for the treatment of large and complicated renal calculi. initially, percutaneous access to the kidney was only performed in the prone position, as described sixty years ago.

Eligibility criteria:
inclusion criteria: * patients who underwent percutaneous nephrolithotomy * patient's age from \>18 - 70 years old. * body mass index (30-40 kg/m2). * both sex * renal stones diameter ≥2 cm * cardiac patients exclusion criteria: * patient refusal. * pregnant women. * patients with renal anomalies. * transplanted kidney. * uncorrected coagulopathy, or active infection.
marginal integrity and clinical evaluation of polyetheretherketone (peek) versus lithium disilicate (e-max) endocrowns.

Conditions: Endodontically Treated Teeth

Summary: patients need endocrowns for their teeth usually use emax as an etchable ceramic. yet they have disadvantages that may influence the outcome of the endocrowns, among which is the high stiffness and rigidity owing to the higher modulus of elasticity (67.2 gpa)( compared to natural dentin (18.6 gpa) which may affect the marginal adaptation.so a less rigid material is needed. peeks (polyetheretherketones) are presented as alternative materials to metal and glass ceramics, their elastic modulus comparable to those of cortical bone and dentin so the polymer could exhibit good stress distribution. also they have high fracture resistance, and low abrasion to the antagonist enamel. .but the investigators have to know clinically it is performance , so the investigators are going to have parallel groups in a randomized clinical trial.


Eligibility criteria:
inclusion criteria: all subjects are required to be: * from 18-60 years old, and able to read and sign the informed consent document. * physically and psychologically able to tolerate conventional restorative procedures * have no active periodontal or pulpal diseases. * willing to return for follow-up examinations and evaluation exclusion criteria: * patients in the growth stage with partially erupted teeth * patient with fractured teeth of more than 50% enamel loss * patients with poor oral hygiene and motivation * pregnant women * psychiatric problems or unrealistic expectations * lack of opposite occluding dentition in the area intended for restoration
lower silesia culotte bifurcation registry (lscbr).

Conditions: Safety Issues; Efficacy, Self

Summary: the study aimed to evaluate the outcomes of bifurcation pci using two techniques (culotte vs. dk-culotte) using data from a retrospective analysis.

the study contains a retrospective analysis of subjects who have undergone pci in two high-volume cooperative cardiac departments in the lower silesia region (poland) between april 2012 and january 2024. data regarding all performed pci from these periods were prescreened in terms of bifurcation lesion with subsequent implantation of two stents using the culotte technique or the dk-culotte technique. the indication for percutaneous coronary intervention (pci) was based either on a judgment made by the heart team or on a particular clinical indication (ongoing ischemia, lack of will for the alternative treatment options, presence of significant angiographic cad suitable for pci due to esc/esh recommendation). the decision to perform the two-stent technique pci was left to the operator's dissertation based on clinical and angiographical features. all patients were thoroughly informed about all therapeutic options and pci-related risks before providing written informed consent for the procedure. there were no clinical or vessel-related exclusion criteria (lesion anatomy, length, tortuosity, severity). however, patients who had undergone pci with coronary stents prior to the index procedure with respect to the bifurcation lesion studied were excluded from the study.

Eligibility criteria:
inclusion criteria: * presence of significant changes in the coronary bifurcation requiring the implantation of two coronary stents using the culotte or dk culotte technique. exclusion criteria: * patients who underwent pci with coronary stents prior to the index procedure for the bifurcation lesion studied.

Keywords: percutaneous coronary intervention (pci) bifurcation lesion culotte technique double kiss culotte technique acute coronary syndrome two-stent technique
efficacy and safety of a new multi-dose lubricant eye drop concomitant with restasis® (cyclosporine a) for the treatment of dry eye symptoms

Conditions: Dry Eye

Summary: to evaluate the efficacy, safety and tolerability of a combination of optive® artificial tears with restasis®.the primary hypothesis is that the ocular surface disease index (osdi) score and symptoms will be the same or lower than baseline after treatment in these patients. the patients will tolerate the combination of restasis® and optive® with a low incidence of clinical adverse events.


Eligibility criteria:
inclusion criteria: * · males or females \> 18 years old * patients currently taking restasis® for at least 3 months in duration and using artificial tears as needed for dry eye. * likely to complete all study visits and able to provide informed consent exclusion criteria: * · patients using restasis® for less than 3 months. * known contraindications to any study medication or ingredients * female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females. * other active uncontrolled ocular diseases or uncontrolled systemic disease